A subset of COVID-19 patients treated with anakinra, a recombinant form of endogenous IL-1Ra that blocks IL-1 activity, experienced a significant reduction in C-reactive protein levels, superior improvement in respiratory functions, and a higher cumulative survival rate compared to patients not treated with anakinra, indicating that the NLRP3 inflammasome is a potential target for COVID-19 therapy (Iglesias-Julian et al., 2020; Kyriazopoulou et al., 2021). The gene discussed is IL1B; the disease is COVID-19.